Clinical experience of levetiracetam monotherapy for adults with epilepsy: 1-year follow-up study  by Alsaadi, Taoufik M. et al.
Seizure (2005) 14, 139—142www.elsevier.com/locate/yseizClinical experience of levetiracetam
monotherapy for adults with epilepsy:
1-year follow-up studyTaoufik M. Alsaadi*, Alan Shatzel, Anna Vinter Marquez,
Julie Jorgensen, Sarah FariasDepartment of Neurology Epilepsy Program, University of California Davis,
4860 Y Street, Suite 3700, Sacramento, CA 95817, USAKEYWORDS
Partial seizures;
Monotherapy;
Levetiracetam
Summary We identified 46 patients with a history of partial seizures, with and
without secondarily generalization, who received levetiracetam (LEV) (Keppra1)
monotherapy. Patients began LEV either as first line therapy (n = 11) or were con-
verted to LEV monotherapy (n = 35) after failing prior antiepileptic medications
(AEDs). Patients were followed up to 12 months after LEV started. The majority of
these patients were able to continue on LEV and a small number of patients
discontinued LEV secondary to lack of efficacy. One third of the non-seizure free
group at 6 months of follow-up had worse seizure control at 12 months and two thirds
had the same or better seizure control. Our 1-year follow-up data of LEV as mono-
therapy suggests that LEV can be effective and well tolerated in adults with either
new or difficult to control epilepsy. A prospective, large, long-term double-blind study
is needed to confirm this finding.
# 2004 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.Introduction
The aim of antiepileptic drug (AED) therapy is to
achieve seizure control using a single agent. How-
ever, this can be only successful in approximately
two thirds of patients whether old or new AEDs are
used. 1,2 Levetiracetam (LEV) is a novel antiepilep-
tic drug (AED) which has been approved as adjunc-
tive treatment for adults with partial onset seizures.
Its effectiveness was established in three multicen-* Corresponding author. Tel.: +1 916 734 6265;
fax: +1 916 734 6525.
E-mail address: taoufik.alsaadi@ucdmc.ucdavis.edu
(T.M. Alsaadi).
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doi:10.1016/j.seizure.2004.12.006ter, well-controlled pivotal trials. 3—5 In addition,
LEV is well tolerated with a favorable pharmacoki-
netic profile that includes minimal protein binding,
lack of hepatic metabolism, and twice a day dosing.
6 These features and others make it ideal for use as
monotherapy.
We have previously demonstrated the efficacy of
levetiracetam as monotherapy in newly diagnosed
naı¨ve epilepsy patients and in patients with chronic
difficult to control epilepsy who were followed for 6
months. 7 However, the efficacy and long-term con-
tinuation rate of LEV monotherapy at 1 year of
treatment is currently unknown. In this study, we
sought to evaluate our 1-year experience with LEV
monotherapy, examining the seizure control andby Elsevier Ltd. All rights reserved.
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Table 1 Demographics and characteristics of the con-
version to LEV monotherapy group.
Variable LEV (n = 35)treatment retention rates in our clinic population
and comparing them with our 6 months clinical
experience.Mean age
(years) (S.D.)
41.1 (15.8)
Gender
(% male/female)
35/65
Age at epilepsy
onset (years) (S.D.)
31.3 (23.75)
Mean duration
of epilepsy (years) (S.D.)
13.85 (12.05)
Cause of epilepsy
(% unknown)
21/35 (60)
Cause of epilepsy
(% with MTS on MRI)
7/35 (20)
Mean number of
previous AEDs (S.D.)
2.2 (1.25)
Mean seizure
frequency (n/week) (S.D.)
2.43 (3)
Mean LEV dosage
(mg/day) (S.D.)
2476.19 (852)
MTS, mesial temporal sclerosis.
Table 2 Demographics and characteristics of the
naive LEV monotherapy group.
Variable LEV (n = 11)Methods
In this report, we analyzed the data of 31 patients
previously reported, 7 and an additional 16 patients
were identified after retrospectively reviewing the
medical records of our patients who were diagnosed
with epilepsy after having two unprovoked seizures
during the years 2000—2003. Six of the original 37
patients previously reported were not included
because further evaluation of their diagnosis with
Video-EEG Monitoring revealed diagnosis other than
epilepsy. We identified patients who received LEVas
monotherapy either as a first line or add-on agent
with subsequent conversion to LEV monotherapy.
We reviewed patients’ demographic data, diagnos-
tic evaluation for epilepsy, seizure types, and sei-
zure frequency prior to and following initiation of
LEV monotherapy. All patients had follow-up visits
at regular intervals every 2 months, or at shorter
intervals if medically necessary. All patients had
their LEV dose titrated up to maximal tolerated
dose or up to 5000 mg/day, and for elderly patients
the dose was titrated up to 2000 mg/day or up to
seizure freedom. In this observational study, we
compared seizure counts for the previous 2 months
as baseline, prior to initiation of LEV treatment, to
seizure counts at six months and at 12 months of
follow-up after LEV was started and maintained as
therapy. Seizure frequency was determined using a
seizure diary completed by each patient or their
caregivers, which is a standard practice in our clinic.
The analysis of seizure-freedom and seizure reduc-
tions rates was based on the number of patients who
completed the 1-year follow-up. Adverse events
(AEs) while on LEV were also noted at each clinic
visit. Blood work including CBC, LFTs were obtained
at baseline, 6 months, and at 1 year of treatment.Mean age
(years) (S.D.)
49 (17.9)
Gender
(% male/female)
10/90
Age at epilepsy
onset (years) (S.D.)
47.43 (17.9)
Mean duration
of epilepsy (years) (S.D.)
7.87 (17.84)
Cause of epilepsy
(% unknown)
60
Mean seizure frequency
(n/month) (S.D.)
1.6 (1.3)
Mean LEV dosage
(mg/day) (S.D.)
1625 (876)Results
We identified 46 patients (32 females, 14 males),
ages 18—91, (mean 30.8) with a history of partial
seizures with and without secondarily generaliza-
tion. The duration of epilepsy prior to LEV treatment
ranged from 1—52 years, (mean 14.1 years). Eleven
of these patients began LEV as an initial drug ther-
apy. These patients were not taking any AEDs for any
period of time prior to starting LEV. Three of the 11
patients had liver disease, and the remaining eight
patients chose to start LEV because of its favorablepharmacokinetic and side effect profile. Thirty-five
patients converted to LEV monotherapy after they
failed several trials of AEDs, which included pheny-
toin (Dilantin1), phenobarbital, carbamazepine
(Tegretol1), divalproex sodium (Depakote1) lamo-
trigine (Lamictal1), and topiramate (Topamax1),
(mean 2.2 AEDs). Characteristics and demographics
of our two groups of patients are summarized in
Tables 1 and 2.
At 6 months visit, three patients were lost to
follow-up and five patients discontinued treatment
secondary to lack of efficacy. Three additional
patients discontinued therapy early after starting
treatments on LEV at a dose less than 500 mg/day
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Table 3 Effect of LEV monotherapy on seizure fre-
quency at 6 and 12 months.
Percent reduction
in seizure frequency
6 months 1 year
0—25 12 2.8
26—50 1 5.7
51—75 25 25.7
76—99 17.8 11.4
100 45 54because of side effects, two of whom were started
on LEV as a first line agent. Hence, 35 patients
remained for analysis in this current study. Of these
patients, 26 were converted to LEV after they failed
their prior AEDs.
Table 3 illustrates changes in seizure frequency at
6 months and at 1 year for the whole group (new
onset and chronic epilepsy) as a percentage. At 1
year follow up: nineteen of the 35 (54%) were
seizure free for the past 6 months. Eight patients
who began LEV as monotherapy were seizure free,
whereas the remaining 11 patients who began LEVas
add-on therapy became seizure free. Of the remain-
ing patients, 9/35 (25.7%) had more than 50%, but
less than 75%, seizure reduction and 4/35 (11.4%)
patients had >75% reduction of seizures. One
patient had no significant change in seizure fre-
quency. The remaining two patients had more than
25%, but less than 50%, reduction in seizure fre-
quency.
For the 18 seizure-free patients at 6 months, 17
patients (94%) remained seizure free at 12 months;
whereas, for the 22 non-seizure free patients
at 6 months: 7/22 (31%) patients had worse sei-
zures at 12 months (less than 25% reduction) at 12
months that was not considered clinically relevant
and eight patients (36%) had the same seizure
control. Two patients (9%) had better seizure con-
trol at 1-year follow-up compared to 6 months.
These last 2 patients became seizure free after
achieving more than 75% reduction of seizures at 6
months visit. Five of the 22 patients discontinued
treatment after 6 months secondary to lack of
efficacy.
Six patients reported being nervous or irritable
within two weeks of starting LEV, either as a single
agent (n = 4) or as add-on treatment (n = 2). Of
these patients, three discontinued LEV, while the
other three patients continued on LEV when their
complaints decreased after the first month of ther-
apy. Four patients reported dizziness within days
after starting LEV but were able to continue on LEV.
No other major AEs were reported. No clinically
significant blood abnormalities were detected
throughout the study.Discussion
This study suggests that LEVas monotherapy can be
effective and well tolerated in newly diagnosed
epilepsy patients as well as for chronic epilepsy
patients who failed multiple AEDs prior to LEV
treatment. In addition, this study shows a high
retention rate of LEV with most patients able to
continue on LEV for 12 months. This was true for
naı¨ve epilepsy patients who were never tried on
AEDs, as well as for patients with difficult to con-
trol epilepsy. Of the group as a whole 45% were
seizure free at 6 months and 54% were seizure free
at 12 months of follow-up. One third of the non-
seizure free group at 6 months of follow-up had a
clinically non-relevant worse seizure control at 12
months and two thirds had the same or better
seizure control.
A previous study of 1422 patients exposed to LEV
during its developmental program showed an esti-
mated rate of retention to be 60% after 1 year with
13% of patients becoming seizure free for at least 6
months. 8 In the present study, 82% of our patients
remained on LEV for at least 1 year with more than
50% of patients remaining seizure free. Most of these
patients (60.7%) had failed more than one AED,
while 32% of patients were on dual therapy at the
time of conversion. Other open label add-on studies
confirm this finding. 9,10
Retention rate studies are a measurement of
efficacy and tolerability of an AED. Comparing
retention rates between studies with populations
of different settings may not be ideal. Studies uti-
lizing patients from clinical trials may show higher
retention rates than chronic refractory epilepsy
studies. Patients in clinical trials are less likely to
withdraw than patients in clinical practice, with
many withdrawals, in these clinical trials are due
to problems intrinsic to AED trials. Our higher than
previously reported continuation success rates on
LEV may be related to the small sampling of patients
studied, differences in the severity of underlying
disease, selection bias, as well as the lack of double
blind randomization. In addition, it is possible that
the number of AEDs taken concurrently in the other
add-on trials have an effect on the retention rates,
as patients on LEV monotherapy are more likely to
continue on LEV. Similarly, our lower than previously
reported AEs, including the low psychiatric and
behavioral complaints in this current study could
be related to a lack of pharmacokinetic and phar-
macodynamic interactions in our study. It is well
known that negative psychotropic effects are
increased in patients taking multiple AEDs as com-
pared to those taking a single agent. 11 Patients on
monotherapy have far fewer adverse effects than
142 T.M. Alsaadi et al.patients on polytherapy. This is the distinction
between community practice experience and clin-
ical trials reports.
Finally, the improvement in seizure control could
be the result of spontaneous remission as there
are fluctuations in seizure frequency in epileptic
patients. 12 However, the longer seizures persist,
the harder they are to control. With an average
duration of epilepsy at 13.8 years for the chronic
epilepsy patients, it is unlikely that a complete
spontaneous remission in seizure frequency could
explain all the improvement seen in this population.References
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